+

WO2001070764A3 - Epitopes - Google Patents

Epitopes Download PDF

Info

Publication number
WO2001070764A3
WO2001070764A3 PCT/GB2001/001205 GB0101205W WO0170764A3 WO 2001070764 A3 WO2001070764 A3 WO 2001070764A3 GB 0101205 W GB0101205 W GB 0101205W WO 0170764 A3 WO0170764 A3 WO 0170764A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitopes
mycobacterium tuberculosis
secreted antigens
tuberculosis secreted
absent
Prior art date
Application number
PCT/GB2001/001205
Other languages
English (en)
Other versions
WO2001070764A2 (fr
Inventor
Michel Robert Klein
Original Assignee
Glaxo Group Ltd
Michel Robert Klein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Michel Robert Klein filed Critical Glaxo Group Ltd
Priority to AU2001240897A priority Critical patent/AU2001240897A1/en
Publication of WO2001070764A2 publication Critical patent/WO2001070764A2/fr
Publication of WO2001070764A3 publication Critical patent/WO2001070764A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des épitopes de lymphocytes CD8 T, dérivés à partir de ∫i⊃Mycobacterium tuberculosis∫/i⊃ et correspondant à la formule (I): X1PX2X3X4X5X6X7X8X9 dans laquelle: X1 représente E, X2 représente Y, X3 représente L, X4 représente D, X5 représente P, X6 représente A, X7 représente T, X8 représente V, L, I ou M et X9 est absent; X1 représente L, X2 représente G, X3 représente T, X4 représente A, X5 et X6 représentent chacun V, X7 représente P, X8 représente V, L, I ou M et X9 est absent, X1 représente T, X2 représente A, X3 représente N, X4 représente Q, X5 représente A, X6 représente I, X7 représente S, X8 représente V, L, I ou M et X9 est absent; ou X1 et X7 représentent chacun V, X2 représente W, X3 représente Q, X4 représente P, X5 représente A, X6 représente F, X8 représente F, Y ou W et X9 est absent ou F, Y ou W.
PCT/GB2001/001205 2000-03-20 2001-03-20 Epitopes WO2001070764A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001240897A AU2001240897A1 (en) 2000-03-20 2001-03-20 Epitopes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0006692.8 2000-03-20
GBGB0006692.8A GB0006692D0 (en) 2000-03-20 2000-03-20 Epitopes

Publications (2)

Publication Number Publication Date
WO2001070764A2 WO2001070764A2 (fr) 2001-09-27
WO2001070764A3 true WO2001070764A3 (fr) 2001-12-20

Family

ID=9888005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/001205 WO2001070764A2 (fr) 2000-03-20 2001-03-20 Epitopes

Country Status (3)

Country Link
AU (1) AU2001240897A1 (fr)
GB (1) GB0006692D0 (fr)
WO (1) WO2001070764A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023960A1 (fr) * 1996-11-25 1998-06-04 Isis Innovation Limited Procede de dosage de lymphocytes t specifiques pour un peptide
WO1999051748A2 (fr) * 1998-04-07 1999-10-14 Corixa Corporation Proteines hybrides d'antigenes de mycobacterium tuberculosis et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023960A1 (fr) * 1996-11-25 1998-06-04 Isis Innovation Limited Procede de dosage de lymphocytes t specifiques pour un peptide
WO1999051748A2 (fr) * 1998-04-07 1999-10-14 Corixa Corporation Proteines hybrides d'antigenes de mycobacterium tuberculosis et leurs utilisations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDERSEN AB & HANSEN EB: "Structure and Mapping of Antigene Domains of Protein Antigen b, a 38,000-Molecular-Weight Protein of Mycobacterium tuberculosis", INFECTION AND IMMUNITY, vol. 57, no. 8, August 1989 (1989-08-01), pages 2481 - 2488, XP002026677 *
COLE ST ET AL.: "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence", NATURE, vol. 393, 11 June 1998 (1998-06-11), pages 537 - 544, XP002087941 *
FIRAT H ET AL.: "H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 29, 8 October 1999 (1999-10-08), pages 3112 - 3121, XP002162347 *
WIKER HG ET AL.: "Cloning, expression and significance of MPT53 for identification of secreted proteins of Mycobacterium tuberculosis", MICROBIAL PATHOGENESIS, vol. 26, 1999, pages 207 - 219, XP002177524 *
ZHU X ET AL.: "Specificity of CD8+ T cells from subunit-vaccinated and infected H-2b mice recognizing the 38 kDa antigen of Mycobacterium tuberculosis", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 9, no. 11, November 1997 (1997-11-01), pages 1669 - 1676, XP000925937, ISSN: 0953-8178 *

Also Published As

Publication number Publication date
GB0006692D0 (en) 2000-05-10
WO2001070764A2 (fr) 2001-09-27
AU2001240897A1 (en) 2001-10-03

Similar Documents

Publication Publication Date Title
WO2003028225A3 (fr) Systeme d'indication horaire synchrone sans fil
EP2383290A3 (fr) Régions épitopes d'un récepteur de la thyrotrophine (TSH), leurs utilisations et anticorps les ciblant
AU2002230806A1 (en) Annular recuperator
GC0000166A (en) Compressor starting torque converter.
CA2235145A1 (fr) Commande externe pour la mise en oeuvre multimodale de stations mobiles de systemes de communication radio
MXPA02001258A (es) Sistema de panel estructural.
WO2002102195A3 (fr) Systeme de support de corps
HK1050772A1 (en) A framing method and the synchronous wireless system therewith.
AU2002365275A1 (en) Novel chimeric rev, tat, and nef antigens
WO2001070764A3 (fr) Epitopes
ATE371776T1 (de) Gitterträgerkonstruktion und verbindungsteil, basiselement und verbindungselement hierfür
AP2003002914A0 (en) Novel expression vectors and uses thereof.
AU1087299A (en) Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens
USD488623S1 (en) Felt
USD498593S1 (en) Felt
AU2002303646A1 (en) Vectors having replication, immunogenicity and/or pathogenicity under stress promoter regulation and use thereof
MXPA02000866A (es) Una formulacion bioinsecticida que consiste de bacillus thuringgiensis var. israelensis, y los respectivos procedimientos para su fabricacion.
MY120395A (en) A louvre
AU3593200A (en) (mycobacterium tuberculosis), immunization
GB0008920D0 (en) A novel laminated retroreflective sheet & light- actuated triggering equipement comprising the same
USD508943S1 (en) Type font
Grodowitz et al. Potential Use of Insect Biocontrol Agents for Reducing the Competitive Ability of Hydrilla verticilIata
JP2003298771A5 (fr)
WO2000078933A3 (fr) Nouvelles calpaines et leur utilisation
Perlman Drought and the Maya demise.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载